XML 49 R38.htm IDEA: XBRL DOCUMENT v3.5.0.2
Business combination - Narratives (Details) - ARIAD Pharmaceuticals
$ in Millions
Jun. 01, 2016
USD ($)
Business combinations  
Upfront Payment $ 147.5
Period for additional payment on sales booked 12 months
Period for further transition before provision made 1 year
Fair value of consideration transferred  
Fair value of consideration transferred $ 440.5
Cash 147.5
Contingent consideration 293.0
Acquisition-related contingent consideration $ 293.0
Contingent Consideration  
Fair value of consideration transferred  
Probability of technical success (“PTS”) (as a percent) 25.00%
Projected cash flows period 18 years
Discount rate (as a percent) 10.00%
Minimum  
Business combinations  
Royalties paid, percentage 32.00%
Royalties received, percentage 20.00%
Period for buy back provision 2 years
Maximum  
Business combinations  
Agreement to indemnify the other for breaches of representations and warranties and certain other matters $ 14.0
Royalties paid, percentage 50.00%
Potential future oncology development and regulatory approval milestone payments $ 135.0
Development cost paid $ 7.0
Royalties received, percentage 25.00%
Period for buy back provision 6 years